URGN
UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) has 8 SEC Form 4 filings (16 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 10, 2026.
The most active filer is Chief Medical Officer Schoenberg Mark with 4 filings. Insiders have net sold $1.3M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Elizabeth A. Barrett
- Employees:234
- HQ:Princeton, NJ, US
- IPO:2017-05-04
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.3M
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$2.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 10,000 | $400K | Jul 10 | SEC ↗ | |
| Chief Medical Officer | Sale | 10,000 | $350K | Jun 24 | SEC ↗ | |
| Chief Medical Officer | Sale | 5,222 | $143K | Jun 9 | SEC ↗ | |
Schoenberg MarkFirst filing | Chief Medical Officer | Sale | 10,000 | $300K | May 11 | SEC ↗ |
Smith Jason DrewFirst filing | General Counsel | Sale | 7,479 | $147K | Feb 11 | SEC ↗ |
Related companies
UroGen Pharma Ltd. is in the Healthcare sector.